Sonoma Pharmaceuticals, Inc. 8-K

0001683168-24-001635.txt : 20240322 0001683168-24-001635.hdr.sgml : 20240322 20240322163019 ACCESSION NUMBER: 0001683168-24-001635 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20240321 ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing FILED AS OF DATE: 20240322 DATE AS OF CHANGE: 20240322 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Sonoma Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001367083 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 680423298 STATE OF INCORPORATION: DE FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33216 FILM NUMBER: 24775669 BUSINESS ADDRESS: STREET 1: 5445 CONESTOGA COURT, SUITE 150 CITY: BOULDER STATE: CO ZIP: 80301 BUSINESS PHONE: 800-759-9305 MAIL ADDRESS: STREET 1: 5445 CONESTOGA COURT, SUITE 150 CITY: BOULDER STATE: CO ZIP: 80301 FORMER COMPANY: FORMER CONFORMED NAME: Oculus Innovative Sciences, Inc. DATE OF NAME CHANGE: 20060622 8-K 1 sonoma_8k.htm CURRENT REPORT Sonoma Pharmaceuticals, Inc. 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) March 21, 2024

SONOMA PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-33216		68-0423298
(State or other jurisdiction		(Commission		(IRS Employer
of incorporation)		File Number)		Identification No.)

5445 Conestoga Court, Suite 150

Boulder, CO 80301

(Address of principal executive offices)

(Zip Code)

(800) 759-9305

(Registrant’s telephone number, including area code)

Not applicable.

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading symbol(s)	Name of each exchange on which registered
Common Stock	SNOA	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 3.01

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On March 21, 2024, Sonoma Pharmaceuticals, Inc. (the “Company”) received a notice (the “Extension Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that Nasdaq granted the Company an additional 180 calendar days, or until September 16, 2024 to regain compliance with the minimum closing bid price requirement for continued listing on The Nasdaq Capital Market under Nasdaq Marketplace Rule 5550(a)(2) (the “Rule”). The Extension Notice has no immediate effect on the listing of the Company’s common stock.

As previously disclosed in the Current Report on Form 8-K filed on September 28, 2023 with the Securities and Exchange Commission, the Company received a notice from Nasdaq on September 22, 2023 informing the Company that because the closing bid price for the Company’s common stock listed on Nasdaq was below $1.00 per share for 30 consecutive business days, the Company did not comply with the minimum closing bid price requirement for continued listing on The Nasdaq Capital Market under the Rule. That notification had no immediate effect on the listing of the Company’s common stock. The Company initially had a period of 180 calendar days, or until March 20, 2024, to regain compliance with the Rule. The Company did not regain compliance with the Rule by such date and proactively notified Nasdaq of its intent to cure the deficiency and requested an additional 180 calendar day period to regain compliance with the Rule.

If at any time before September 16, 2024 the closing bid price of the Company’s common stock is at least $1.00 per share for a minimum of 10 consecutive business days, Nasdaq will provide written confirmation that the Company has achieved compliance with the Rule, unless Nasdaq exercises its discretion to extend this 10-day period pursuant to Nasdaq Listing Rule 5810(c)(3).

If compliance with the Rule cannot be demonstrated to Nasdaq’s satisfaction by September 16, 2024, Nasdaq will provide written notification that the Company’s common stock will be delisted. At that time, the Company may appeal Nasdaq’s delisting determination to a Nasdaq Hearings Panel.

The Company intends to continue actively monitoring the bid price for its common stock between now and September 16, 2024 and will consider available options to resolve the deficiency and regain compliance with the Rule. These options include effecting a reverse stock split, if necessary. There is no assurance, however, that the Company will regain compliance with the Rule or that the Company’s common stock will not be delisted from Nasdaq.

This report contains forward-looking statements. Forward-looking statements include, but are not limited to, statements that express the Company’s intentions, beliefs, expectations, strategies, predictions or any other statements related to future activities or future events or conditions. These statements are based on current expectations, estimates and projections about the Company’s business based, in part, on assumptions made by management. These statements are not guarantees of future performances and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including those risks discussed in the Company’s Annual Report on Form 10-K and in other documents that the Company files from time to time with the SEC. Any forward-looking statements speak only as of the date on which they are made, and the Company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this report, except as required by law.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	SONOMA PHARMACEUTICALS, INC.


Date: March 22, 2024	By:	/s/ Amy Trombly
	Name: Title:	Amy Trombly Chief Executive Officer

3

EX-101.SCH 2 snoa-20240321.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 snoa-20240321_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 4 snoa-20240321_pre.xml XBRL PRESENTATION FILE XML 6 R1.htm IDEA: XBRL DOCUMENT

Cover	Mar. 21, 2024
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Mar. 21, 2024
Entity File Number	001-33216
Entity Registrant Name	SONOMA PHARMACEUTICALS, INC.
Entity Central Index Key	0001367083
Entity Tax Identification Number	68-0423298
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	5445 Conestoga Court
Entity Address, Address Line Two	Suite 150
Entity Address, City or Town	Boulder
Entity Address, State or Province	CO
Entity Address, Postal Zip Code	80301
City Area Code	(800)
Local Phone Number	759-9305
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock
Trading Symbol	SNOA
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false

EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://sonomapharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports snoa-20240321.xsd snoa-20240321_lab.xml snoa-20240321_pre.xml sonoma_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "sonoma_8k.htm": { "nsprefix": "SNOA", "nsuri": "http://sonomapharma.com/20240321", "dts": { "schema": { "local": [ "snoa-20240321.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "snoa-20240321_lab.xml" ] }, "presentationLink": { "local": [ "snoa-20240321_pre.xml" ] }, "inline": { "local": [ "sonoma_8k.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://sonomapharma.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-03-21", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "sonoma_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-03-21", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "sonoma_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 14 0001683168-24-001635-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001683168-24-001635-xbrl.zip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end XML 16 sonoma_8k_htm.xml IDEA: XBRL DOCUMENT 0001367083 2024-03-21 2024-03-21 iso4217:USD shares iso4217:USD shares false 0001367083 8-K 2024-03-21 SONOMA PHARMACEUTICALS, INC. DE 001-33216 68-0423298 5445 Conestoga Court Suite 150 Boulder CO 80301 (800) 759-9305 false false false false Common Stock SNOA NASDAQ false